Unknown

Dataset Information

0

Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.


ABSTRACT: Stress and corticotropin-releasing factor (CRF) have been implicated as mechanistically involved in Alzheimer's disease (AD), but agents that impact CRF signaling have not been carefully tested for therapeutic efficacy or long-term safety in animal models.To test whether antagonism of the type-1 corticotropin-releasing factor receptor (CRFR1) could be used as a disease-modifying treatment for AD, we used a preclinical prevention paradigm and treated 30-day-old AD transgenic mice with the small-molecule, CRFR1-selective antagonist, R121919, for 5 months, and examined AD pathologic and behavioral end points.R121919 significantly prevented the onset of cognitive impairment in female mice and reduced cellular and synaptic deficits and beta amyloid and C-terminal fragment-? levels in both genders. We observed no tolerability or toxicity issues in mice treated with R121919.CRFR1 antagonism presents a viable disease-modifying therapy for AD, recommending its advancement to early-phase human safety trials.

SUBMITTER: Zhang C 

PROVIDER: S-EPMC4860182 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.

Zhang Cheng C   Kuo Ching-Chang CC   Moghadam Setareh H SH   Monte Louise L   Campbell Shannon N SN   Rice Kenner C KC   Sawchenko Paul E PE   Masliah Eliezer E   Rissman Robert A RA  

Alzheimer's & dementia : the journal of the Alzheimer's Association 20151107 5


<h4>Introduction</h4>Stress and corticotropin-releasing factor (CRF) have been implicated as mechanistically involved in Alzheimer's disease (AD), but agents that impact CRF signaling have not been carefully tested for therapeutic efficacy or long-term safety in animal models.<h4>Methods</h4>To test whether antagonism of the type-1 corticotropin-releasing factor receptor (CRFR1) could be used as a disease-modifying treatment for AD, we used a preclinical prevention paradigm and treated 30-day-ol  ...[more]

Similar Datasets

| S-EPMC7923248 | biostudies-literature
| S-EPMC8804111 | biostudies-literature
| S-EPMC5828200 | biostudies-literature
| S-EPMC6693625 | biostudies-literature
| S-EPMC2922247 | biostudies-literature
| S-EPMC7176648 | biostudies-literature
| S-EPMC4440804 | biostudies-literature
| S-EPMC7359297 | biostudies-literature
| S-EPMC3004537 | biostudies-literature
| S-EPMC2753494 | biostudies-literature